Sugi Predict

Sugi Predict / Compounds / SCHEMBL19949883

SCHEMBL19949883

SCHEMBL19949883

Cc1cccc(F)c1-c1nc2c(-c3ccc(N4CCN(C)CC4)nc3)n[nH]c2cc1C#N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP4K1 Q92918 9/20 0.46
▸ ACVR1 Q04771 3/20 0.42
▸ FGFR1 P11362 1/20 0.42
▸ FGFR2 P21802 1/20 0.42
▸ FGFR3 P22607 1/20 0.42
▸ BMPR1A P36894 1/20 0.42
▸ TGFBR1 P36897 1/20 0.42
▸ ACVRL1 P37023 1/20 0.42
▸ HAMP P81172 1/20 0.42
▸ TNKS O95271 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.39
▸ USP2 O75604 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ CLK1 P49759 1/20 0.39
▸ PLK4 O00444 2/20 0.39
▸ FLT3 P36888 2/20 0.39
▸ RET P07949 2/20 0.39
▸ TDO2 P48775 1/20 0.39
▸ AURKA O14965 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19949869 0.86 MAP4K1 (0.45) MAP4K1ACVR1FGFR1FGFR2FGFR3
SCHEMBL19949820 0.83 PLK4 (0.40) MAP4K1ACVR1FGFR1FGFR2FGFR3
SCHEMBL19949817 0.82 MAP4K1 (0.42) MAP4K1USP2ALDH1A1TSHR
SCHEMBL19949886 0.81 MAP4K1 (0.53) MAP4K1FGFR1FGFR3FLT3
SCHEMBL19949819 0.80 MAP4K1 (0.47) MAP4K1FGFR1FGFR2FLT3RET
SCHEMBL19949940 0.78 MAP4K1 (0.41) MAP4K1
SCHEMBL19949764 0.75 MAP4K1 (0.46) MAP4K1ACVR1FGFR1FGFR2FGFR3
SCHEMBL24418315 0.75 TNKS (0.46) MAP4K1ACVR1FGFR1FGFR2FGFR3
SCHEMBL29606913 0.75 TNKS (0.46) MAP4K1ACVR1FGFR1FGFR2FGFR3
SCHEMBL19960797 0.74 MAP4K1 (0.46) MAP4K1ACVR1FGFR1FGFR2FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12516059-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2026-01-06 — — US claimed
US-20240383889-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2024-11-21 — — US claimed
US-20190315743-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2019-10-17 — — US claimed
US-20180072718-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 — — US claimed
US-12516059-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2026-01-06 — — US disclosed
US-20240383889-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2024-11-21 — — US disclosed
US-11891388-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2024-02-06 — — US disclosed
US-20230338389-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2023-10-26 — — US disclosed
US-20230338389-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2023-10-26 — — US disclosed
US-20220227752-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2022-07-21 — — US disclosed
US-11242343-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2022-02-08 — — US disclosed
US-11242343-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2022-02-08 — — US disclosed
US-20200283434-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2020-09-10 — — US disclosed
US-20200283434-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2020-09-10 — — US disclosed
US-20190315743-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2019-10-17 — — US disclosed
US-20190315743-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2019-10-17 — — US disclosed
WO-2018049214-A1 PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER INCYTE CORPORATION (US) 2018-03-15 — — WO disclosed
US-20180072718-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 — — US disclosed
US-20180072718-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 — — US disclosed
US-20180072718-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383889-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 MAP4K1 41/4885ACVR1 4405/4885FGFR1 3938/4885
US-11242343-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 MAP4K1 41/4885ACVR1 4405/4885FGFR1 3938/4885
US-20190315743-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 MAP4K1 41/4885ACVR1 4405/4885FGFR1 3938/4885
US-20180072718-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 MAP4K1 41/4885ACVR1 4405/4885FGFR1 3938/4885
US-20200283434-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 MAP4K1 41/4885ACVR1 4405/4885FGFR1 3938/4885
US-20220227752-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 MAP4K1 41/4885ACVR1 4405/4885FGFR1 3938/4885
US-11891388-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 MAP4K1 41/4885ACVR1 4405/4885FGFR1 3938/4885
US-20230338389-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 MAP4K1 1403/4885ACVR1 161/4885FGFR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.